Valuation models
price $414.50 · as of Nov 2, 2026
DCF · Perpetuity growth · 5yused195.55 – 355.81257.7261% overvaluedDCF · Perpetuity growth · 10y203.87 – 371.92268.9354% overvaluedDCF · EBITDA exit · 5y412.61 – 457.46434.425% undervaluedDCF · EBITDA exit · 10y381.02 – 462.98419.991% undervaluedP/E · peers125.66 – 385.18139.56197% overvaluedP/E · own history177.34 – 238.34209.2898% overvaluedPEG—228.9881% overvaluedEV/EBITDA · peers159.95 – 425.95255.1462% overvaluedEV/Revenue · peers273.14 – 635.85421.402% undervaluedEarnings power value116.23 – 210.70154.00169% overvaluedDividend discount74.66 – 182.32112.60268% overvaluedWall St. consensus target—495.0016% belowCost of capital (WACC)—7.49%—
DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. How the headline model is chosen.
Model value · DCF · Perpetuity growth · 5y
257.72
Humana closed at $414.50 — overvalued by 61% vs model.
195.55the model's range355.81
DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.
Other models
112.60 – 434.42
Wall St. target
495.00 16% below
Above model, 1y
16 of 30 days
How it is valued
Valued asMature & stable
Moderate growth (~10% recent)Thin margins (0.9% net margin)Highly cyclical earnings
Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; how each model works is in the manual.